Actelion and GSK drop Phase III insomnia drug
This article was originally published in Scrip
Executive Summary
The Swiss biopharmaceutical firm Actelion and its multinational partner GlaxoSmithKline have dropped development of their chronic insomnia treatment, almorexant, which had reached the Phase III trials.However, the orexin receptor antagonist was already troubled by safety concerns back in 2009 (scripintelligence.com, 21 December 2009).